checkAd

     218  0 Kommentare Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt - Seite 3

    Other risks and uncertainties include those identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (SEC) on March 18, 2021 and in any subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Verastem Oncology’s views as of the date hereof, and the Company does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

    Lesen Sie auch

    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt - Seite 3 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has converted all of the $28.0 million aggregate principal of the Company’s 2020 5.00% …

    Schreibe Deinen Kommentar

    Disclaimer